A randomized, open-label study of the tolerability and efficacy of one or three daily doses of ivermectin plus diethylcarbamazine and albendazole (IDA) versus one dose of ivermectin plus albendazole (IA) for treatment of onchocerciasis
- Nicholas O. Opoku
- , Felix Doe
- , Bettina Dubben
- , Nicole Fetcho
- , Kerstin Fischer
- , Peter U. Fischer
- , Shelter Gordor
- , Charles W. Goss
- , Michael E. Gyasi
- , Achim Hoerauf
- , Augustine Hong
- , Eric Kanza
- , Christopher L. King
- , Ruth Laryea
- , Daphne Lew
- , Mahmood A. Seidu
- , Gary J. Weil
- Division of Infectious Diseases
- Roy and Diana Vagelos Division of Biology & Biomedical Sciences (DBBS)
- Institute of Clinical and Translational Sciences (ICTS)
- Institute for Informatics, Data Science and Biostatistics (I2DB)
- Department of Ophthalmology and Visual Sciences
- Center for Applied Health Informatics (CAHI)
- Bursky Center for Human Immunology and Immunotherapy
- COVID-19 Researchers
- DBBS - Evolution, Ecology and Population Biology
- DBBS - Molecular Microbiology and Microbial Pathogenesis
- Center for Biostatistics and Data Science (CBDS)
- DBBS - Biomedical Informatics and Data Science
- Rheumatic Diseases Research Resource-Based Center
Research output: Contribution to journal › Article › peer-review
6
Link opens in a new tab
Scopus
citations